<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056705</url>
  </required_header>
  <id_info>
    <org_study_id>imbcams-02</org_study_id>
    <secondary_id>SFDA2007L02021</secondary_id>
    <nct_id>NCT01056705</nct_id>
  </id_info>
  <brief_title>The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)</brief_title>
  <acronym>Sabin IPV</acronym>
  <official_title>The Phase Ⅱ Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangxi Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for the Control of Pharmaceutical and Biological Products, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on pre-clinical trial and phase 1 clinical data and principle of GCP, the objective of
      phase Ⅱ clinical trial is to evaluate safety and immunogenicity of Inactivated Poliomyelitis
      Vaccine made from Sabin Strains(Sabin IPV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Sabin IPV was manufactured with poliovirus type1, 2, 3 Sabin strains and Vero cells by
      microcarrier culture in 550 liter bioreactors. The virus suspension was harvested
      ,ultra-concentrated, purified and inactivated with formalin. Three formulations A,B,C of
      Sabin IPV were used, the DAg contents for A were type1 45,type2 64,type3 67.5 DU /0.5ml/per
      dose; for B 30,32,45 DU/0.5ml/per dose; for C 15,16,22.5 DU/0.5ml/per dose.

      Oral Poliomyelitis Vaccine(OPV)was manufactured by Institute of Medical Biology, Chinese
      Academy of Medical Sciences.Trivalent OPV contains Polioviruses Type 1 6.0 log CCID Type 2
      5.0 log Type 3 5.5log /0.1ml/per dose Inactivated Poliomyelitis Vaccine (Salk strains)was
      manufactured by Sanofi Pasteur DAg contents /0.5ml/per dose were Type 1 40 DU,Type 2 8DU,Type
      3 32DU.

      This is a randomized, blind phase 2 clinical trial. Total 500 infants (ages 60 days to 90
      days) were selected , randomized to five groups(each group n=100) Sabin IPV formulations
      A,B,C,OPV ,Salk IPV were separately given to each group with three doses one month apart
      respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains by different does on Healthy infants .</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Experiment Infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Experiment infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Experiment infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Experiment infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Experiment infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Poliomyelitis Vaccine (Sabin strains)</intervention_name>
    <description>Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.</description>
    <arm_group_label>Cohort 1: Experiment Infants</arm_group_label>
    <other_name>Sabin IPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Poliomyelitis Vaccine (Sabin strains)</intervention_name>
    <description>Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.</description>
    <arm_group_label>Cohort 2: Experiment infants</arm_group_label>
    <other_name>Sabin IPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Poliomyelitis Vaccine (Sabin strains)</intervention_name>
    <description>Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.</description>
    <arm_group_label>Cohort 3: Experiment infants</arm_group_label>
    <other_name>Sabin IPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oral Poliomyelitis Vaccine</intervention_name>
    <description>Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.</description>
    <arm_group_label>Cohort 4: Experiment infants</arm_group_label>
    <other_name>OPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Poliomyelitis Vaccine (Salk strains).</intervention_name>
    <description>3x0.5ml intramuscular injections, one month apart.</description>
    <arm_group_label>Cohort 5: Experiment infants</arm_group_label>
    <other_name>Salk IPV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, age from 60 days to 90 days;

          -  Adults, parent(s) or guardians are able to understand and sign informed consent for
             participation;

          -  Participants or guardians are able to attend all planned clinical appointment and obey
             and follow all study instructions;

          -  Infants no vaccinated with poliovaccine or other preventive biologicals in recent 7
             days;

          -  Axillary temperature ≤37℃.

        Exclusion Criteria:

          -  Have medical record of participants or their family on allergy, convulsion, falling
             sickness, encephalopathy and psychopathy;

          -  Low platelet or bleeding disorder do not allow vaccination into the muscle;

          -  Have damaged or lower immunological function;

          -  Received blood, plasma or immunoglobulin treatment since birth;

          -  Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic (
             Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );

          -  Have or be doubtful of following diseases: respiratory system diseases, acute
             infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin
             diseases, HIV.

        Exclusion Criteria for doses 2 and 3

          -  Have serious anaphylaxis or high fever, convulsion during first dose;

          -  Have any circus of Exclusion Criteria after Eligible for study;

          -  Have serious adverse event which related to previous vaccination; Withdrawal and
             Discontinuance Criteria;

          -  Received necessary or interference study drugs such as: immune-inhibition or
             immune-stimulating agents;

          -  Vaccinated with any other vaccine（except DTP）;

          -  Stop observation determined by investigator owing to occurring serious adverse event;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liao Guoyang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Rongcheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Changgui, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for the Control of Pharmaceutical and Biological Products, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pingle Center for Disease Control and Prevention</name>
      <address>
        <city>Pingle county</city>
        <state>Guangxi</state>
        <zip>542400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>July 31, 2016</last_update_submitted>
  <last_update_submitted_qc>July 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Guoyang Liao</investigator_full_name>
    <investigator_title>Head of Biologicals No.5</investigator_title>
  </responsible_party>
  <keyword>Inactivated Poliomyelitis Vaccine</keyword>
  <keyword>Sabin Strains</keyword>
  <keyword>poliomyelitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

